Article
In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment.
Antimicrobial agents and chemotherapy - 1 Aug 2014
Cannatelli Antonio, Di Pilato Vincenzo, Giani Tommaso, Arena Fabio, Ambretti Simone, Gaibani Paolo, D'Andrea Marco Maria, Rossolini Gian Maria
Abstract excerpt
Colistin is a key drug for the treatment of infections caused by extensively drug-resistant strains of Enterobacteriaceae producing carbapenemases. However, the emergence of colistin resistance is being increasingly reported, especially among Klebsiella pneumoniae strains producing KPC-type carbapenemases (KPC-KP). In this work, we investigated colistin-susceptible (KPB-1) and colistin-resistant (KPB-2)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
